Acquisition by Jeffrey Wade of 314320 shares of Lexicon Pharmaceuticals subject to Rule 16b-3

LXRX Stock  USD 0.79  0.01  0.76%   
Slightly above 62% of all Lexicon Pharmaceuticals' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Lexicon Pharmaceuticals suggests that some traders are interested. Lexicon Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Lexicon Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Lexicon Pharmaceuticals I officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
Lexicon insider trading alert for grant of restricted stock units by Jeffrey Wade, President and CFO, on 12th of February 2024. This event was filed by Lexicon Pharmaceuticals I with SEC on 2024-02-12. Statement of changes in beneficial ownership - SEC Form 4. Jeffrey Wade currently serves as cfo, executive vice president - corporate development of Lexicon Pharmaceuticals

Cash Flow Correlation

Lexicon Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Lexicon Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Lexicon Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Lexicon Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Lexicon Pharmaceuticals Fundamental Analysis

We analyze Lexicon Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lexicon Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lexicon Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

EBITDA

EBITDA Comparative Analysis

Lexicon Pharmaceuticals is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Lexicon Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lexicon Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Lexicon Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Lexicon Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Lexicon Pharmaceuticals Related Equities

XFORX4 Pharmaceuticals   11.43   
0%
100.0%
TERNTerns Pharmaceuticals   7.82   
0%
68.0%
HOOKHookipa Pharma   6.90   
0%
60.0%
ARDXArdelyx   6.36   
0%
55.0%
MREOMereo BioPharma   4.71   
0%
41.0%
MCRBSeres Therapeutics   4.55   
0%
39.0%
BLRXBioLineRx   3.57   
0%
31.0%
ENVBEnveric Biosciences   3.13   
0%
27.0%
DAWNDay One   1.33   
0%
11.0%
IBRXImmunitybio   0.39   
3.0%
0%
ELEVElevation Oncology   1.59   
13.0%
0%
OCEAOcean Biomedical   2.74   
23.0%
0%
HEPAHepion Pharmaceuticals   4.48   
39.0%
0%

Additional Tools for Lexicon Stock Analysis

When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.